

## Product Specification Sheet

**Product Name:** ABT-263 (Navitoclax)

**Catalog Number:** C2263

### Technical information:

**Chemical Formula:** C<sub>47</sub>H<sub>55</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>6</sub>S<sub>3</sub>

**CAS #:** 923654-51-6

**Molecular Weight:** 974.61

**Purity:** > 98%


**Appearance:** white solid

**Solubility:** Soluble in DMSO up to 100 mM

**Chemical Name:** (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide

**Storage:** Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

**Shelf Life:** In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months under proper storage condition.



**Handling:** • To make 10 mM stock solution, add 0.103mL of DMSO for each mg of ABT-263 (Navitoclax).

- For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum sample recovery.

**Biological Activity:** ABT-263 is an orally-available Bcl-2 family inhibitor with Ki values of <1 nM for Bcl-2, Bcl-xL, and Bcl-w. ABT-263 disrupts key Bcl interactions with proteins such as Bim, inducing apoptosis. Despite being a Bad-like Bh3 mimetic, ABT-263 has been shown to possess cytotoxic activity and induce apoptosis based primarily on its Bcl-2 family inhibitory activity.

ABT-263 as a standalone agent has modest activity in lymphoma and myeloma xenografts, but is extremely effective in enhancing the efficacy of clinically relevant therapies such as rituxumab and bortezomib. (1)

In a panel of small cell lung cancer (SCLC) xenografts, including H146, H889, and H1963 models, ABT-263 displays excellent antitumor effects, leading to tumor regression. (2)

- Reference:**
1. Tse et al., ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor. *Cancer Res.* 2008, 68, 3421-3428. Pubmed ID: 18451170
  2. Shoemaker et al., Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models. *Clin. Cancer Res.* 2008, 14, 3268-3277. Pubmed ID: 18519752

To reorder: <http://www.cellagentech.com/ABT-263-Navitoclax/>

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*Chemicals are sold for research use only, not for clinical or diagnostic use.*